The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Canadian Health Minister Allan Rock recently announced $600,000 funding for two joint health surveillance initiatives: ACES (Acute Coronary Syndrome Extended Surveillance) and the Canadian Cardiovascular Database. These projects are the first steps in creating a national database of cardiovascular health information that can be used to improve the quality of health care for Canadians and contribute to the effective use of Canada's health resources. The Canadian Cardiovascular Database will track information about individual patients who have heart by-pass surgery or an angioplasty. This will be achieved by linking waiting lists and cardiac care resources nationally through the Internet, making the best use of existing cardiac care facilities and identifying gaps in the system. ACES will combine patient information for clinical and research purposes into one national database. Instead of writing patient information on charts, doctors and nurses will enter bedside data on a pen-based computer, making data collection faster, easier, more accurate and ready to share among health professionals, including researchers. ACES will initially focus on the immediate and long-term treatment of heart attacks.
Genzyme Corp. has entered into a research collaboration with a research group at The Toronto Hospital to develop and commercialize cell-based therapies to treat cardiovascular disease. The research group is lead by Richard Weisel, M.D., a cardiac surgeon at The Toronto Hospital. The partners will focus initially on developing a treatment in which a patient's own cardiac muscle cells (cardiomyocytes) are used to replace damaged heart tissue. This treatment will involve the transplantation of cultured autologous cardiomyocytes into the scar tissue that replaces heart muscle following a heart attack.
Diagnostic Chemicals Limited (DCL) has received a Canadian medical device license to market ZstatFlu, a POC flu test produced by ZymeTx, Inc., in Canada. DCL has assisted in the contract manufacturing of ZstatFlu. DCL will market ZstatFlu during the North American flu season to long-term care facilities, hospitals and physicians' offices.
Healthcare in Canada - December 1998
Healthcare in Canada - November 1998
Healthcare in Canada - October 1998
Healthcare in Canada - September 1998
Healthcare in Canada - August 1998
Healthcare in Canada - July 1998
Healthcare in Canada - June 1998
Healthcare in Canada - May 1998
Healthcare in Canada - April 1998
Healthcare in Canada - March 1998
Healthcare in Canada - February 1998
Healthcare in Canada - January 1998
Healthcare in Canada - July 1997
Healthcare in Canada - June 1997
Healthcare in Canada - May 1997
Healthcare in Canada - April 1997
Healthcare in Canada - March 1997
Healthcare in Canada - February 1997
Healthcare in Canada - January 1997
Healthcare in Canada - December 1996
Healthcare in Canada - November 1996
Healthcare in Canada - October 1996
Healthcare in Canada - September 1996
Healthcare in Canada - August 1996
Healthcare in Canada - July 1996
Healthcare in Canada - June 1996
Concept and Design Blue Page Productions
Copyright © 1996-1999 STRATCOM
Last modified: January 31, 1999